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2Abstract
Background: Low estimated glomerular filtration rate (eGFR) and increased urinary albumin-
to-creatinine ratio (ACR) are well-recognised prognostic markers of cardiovascular (CV) risk,
but their individual and combine relationship with CV disease and total mortality among
insulin-treated Type 2 Diabetes (T2D) patients in routine clinical care is unclear.
Methods: We analysed data for insulin users with T2D from UK general practices between
2007 and 2014 and examined the association between mortality rates and CKD [categorised by
low eGFR (<60mL/min/1.73 m2); high eGFR (≥60mL/min/1.73 m2); low ACR (<300mg/g);
and high ACR (≥300mg/g) at insulin initiation] after a 5-year follow-up period using Cox 
proportional hazard models.
Results: A total of 18,227 patients were identified (mean age: 61.5±13.8 years, mean HbA1c:
8.6±1.8%). After adjusting for confounders, when compared to adults on insulin therapy with
an eGFR <60 and an ACR ≥300 (low eGFR + high ACR) after a follow up period of 5 years, 
patients with an eGFR <60 and an ACR <300 (low eGFR + low ACR) had a 6% lower mortality
rate (aHR: 0.94; 95%CI: 0.79 to1.12); those with an eGFR >60 and an ACR ≥300 (high eGFR 
+ high ACR) had a 20% lower mortality rate (aHR: 0.80; 95%CI: 0.68 to 0.96); and those with
an eGFR >60 and an ACR <300 (high eGFR + low ACR) had the lowest death rate (28% less;
aHR: 0.72; 95%CI: 0.59 to 0.87 ).
Conclusion: This study shows that among a large cohort of insulin-treated T2D patients in
routine practice, the combination of reduced eGFR with increased ACR was associated with
the greatest risk of premature death, followed closely by those with reduced eGFR and normal
ACR levels. Adoption of aggressive CV risk management strategies to reduce mortality in
patients with a low eGFR and albuminuria is essential in these high risk patients with T2D.
3Introduction
Several high impact studies have identified the elevated risk of end stage renal disease (ESRD)
and cardiovascular (CV) disease conferred by albuminuria in addition to estimated Glomerular
Filtration Rate (eGFR) [1-4]. These two distinct but complimentary methods to assess for the
presence of chronic kidney disease (CKD) are widely used in routine clinical practice, with
CKD due to diabetic nephropathy affecting 30-40% of patients with type 2 diabetes (T2D) [5].
Albuminuria is typically assessed by urinary albumin to creatinine ratio (ACR). Elevated ACR
denote the presence of CKD, independent of eGFR categories [6,7]. ACR levels between
30mg/g to 300mg/g, represent moderately increased levels of albuminuria, known as
microalbuminuria, while levels of more than 300mg/g is associated with frank proteinuria.
Estimated Glomerular Filtration Rate (eGFR) is a key indicator of renal function and is
mathematically derived based on a patient’s serum creatinine level, age, sex and race and
calculated using the well validated formulae derived from the Modification of Diet in Renal
Disease (MDRD) CKD-EPI equations [8]. “Normal” eGFR is usually >90 ml/min/1.73m2,
corrected for body surface area “per 1.73m2” which is important for certain patient groups, e.g.
amputees, extremes of body habitus, but in the absence of any marker of kidney damage, eGFR
is only classified as CKD if its value is <60 ml/min/1.73m2 [9].
For many patients with T2D, insulin treatment will be required to control hyperglycaemia an
to reduce the risk of long-term vascular complications in patients with T2D. [10-12]. However,
insulin therapy is known to induce ~4-9 kg weight gain in the first year of treatment. [13] This
is relevant within the context of diabetic nephropathy since obesity per se is a significant risk
factor for the appearance of proteinuria and ESRD [14]. Furthermore, recent evidence from
randomized controlled trial, epidemiological and observational studies have implicated insulin
therapy in patients with T2D with increased CV risk and mortality of [15-18], possibly due to
4weight gain, recurrent hypoglycaemia, other potential adverse effects such as iatrogenic
hyperinsulinemia as well as a surrogate marker of increased diabetes duration [19,20]. Thus, a
cohort of insulin treated patients with T2D, represent a complex heterogenous, challenging
group of patients, many of whom have significant comorbidities and high CV disease risk. No
studies have assessed the relative strength of increments in urinary ACR and/or decrement in
eGFR in predicting total mortality among insulin treated patients with T2D in routine clinical
care.
Methods
Study Design
We conducted a retrospective cohort study using the UK primary care electronic database
called The Health Improvement Network (THIN) Database.
THIN comprises longitudinal records which were obtained from about 587 General Practices
and updated periodically. It contains medical information of over 12.4 million patients in which
approximately 3.61 million are active users. Trained doctors and specialist nurses
systematically enter routine clinical information into this database. These range from specialist
medical consultations, diagnoses, laboratory results, prescriptions, referrals, hospital
admissions, immunisations and clinical measurements as body weight, height and body mass
index (BMI). It also has data on the patients’ demography, lifestyle characteristics (e.g. alcohol
use and smoking), socio-economic status (Townsend deprivation scores), ethnicity, religion
and more recently, ethnicity/languages. It has been validated and shown it to be
demographically representative of the UK population in terms of disease demography -
prevalence and mortality [21]. Like many others, our research group has extensively used it in
evaluating diabetes-related outcomes in routine clinical practice [22,23]
Study Participants
We obtained routine clinical data on 18,227 people with a diagnosis of T2D who met our
inclusion criteria. These must be aged 18 years and above; commenced insulin therapy between
December 2006 and May 2014; and with recorded values of albumin-creatinine ratio (ACR)
5and e-GFR on insulin initiation. Patients with type 1, gestational diabetes, or other forms of
diabetes; and those with no continuous records of regular insulin prescriptions were excluded.
Follow-up and Endpoints
The baseline (insulin initiation) ACR (mg/g) and eGFR (mls/min/1.73m2) levels were used to
categorise the patients into four treatment groups:
Group 1: Low eGFR + High ACR – those with eGFR <60 and an ACR ≥300   
Group 2: Low eGFR +Low ACR – those with eGFR <60 and an ACR <300
Group 3: High eGFR + High ACR – those with   eGFR ≥60 and an ACR ≥300  
Group 4: High eGFR + Low ACR – those with eGFR ≥60 and an ACR <300 
The primary endpoint was all-cause mortality. Secondary endpoints were the risks of
cardiovascular events (non-fatal stroke and myocardial infarction) and a 3-point composite of
MACE (Major Adverse Cardiovascular Event - all-cause mortality, non-fatal myocardial
infarction, and stroke).
From the baseline period, these groups were followed up till the first of the occurrence of death
or loss to follow-up; or discontinuation of insulin therapy; or at the end of the 5-year follow-
up period.
Baseline and endpoint characteristics
We also obtained data on important clinical covariates that confound the association between
the exposure and outcome variables. This is based on a priori knowledge and from the tests of
association. Significant covariates were fitted in the final model in order to adjust for their
possible confounding effects. Therefore, data were extracted for demographic variables such
as age, gender, socioeconomic status, alcohol and smoking status; important clinical measures
such as body weight, height, SBP and DBP; biochemical parameters, e.g. baseline HbA1c,
lipid-profile, use of other medications including other glucose-lowering therapies (GLTs); as
well as comorbidity status, duration of diabetes treatment, and duration of insulin use. These
were included in our univariate analysis models from which significant covariates (those which
6had a significant association with both the exposure and outcomes) were added to the final Cox
models.
Statistical Analysis
Subjects with missing values for eGFR and ACR at baseline were further excluded. A small
proportion of HbA1c, eGFR, weight, SBP and DBP records at baseline were completely
missing at random (MAR). These missing values were then computed using multiple
imputations using the chained equation (MICE) model.
We computed summary data for the mean, standard deviations and proportions of the baseline
characteristics. Differences between the baseline categorical and continuous variables within
the four groups were compared using Pearson’s chi-squared test and linear regression
respectively.
Mortality rates were presented as 5-year Kaplan-Meier estimates. Cox proportional hazard
model was used to estimate the marginal and adjusted mortality ratios (HRs) with 95%
confidence intervals, comparing the mortality in all the groups to Group 1 (Low eGFR + High
ACR). In our multivariate Cox regression models in which we evaluated the association
between poor renal function and all-cause mortality, the identified significant baseline
covariates were included.
We did further Cox regression analysis to explore the risk of cardiovascular events (non-fatal
stroke and myocardial infarction) and a 3-point composite of MACE (Major Adverse
Cardiovascular Event) including all-cause mortality, non-fatal myocardial infarction and
stroke; in the patient groups.
We tested for violations of the proportional hazard assumption of the Cox regression model,
first by adding an interaction term of the predictor; secondly by log-minus-log survival curves;
and thirdly by Schoenfeld residuals tests.
All the point estimates were computed with 95% confidence intervals (CI) at the conventional
statistical significance level of 0.05, using Stata Software version 15.
Ethical Approval:
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Results
Patient Characteristics.
Only 18,227 patients in the dataset met our inclusion criteria in which group 2 had the least
number of patients (13.8%). The overall mean age was 61.5±14 years. Slightly above half
(53.2%) of the population were males. The overall mean HbA1c and BMI were 8.7±1.8%
(72mmol/mol) and 32.5±6.9kg/m2 respectively. These are summarised in Table 1.
The mean eGFR was 62.9±21.2 and this significantly increased from group 1 to 4 (p < 0.001).
Systolic BP slightly reduced across the groups (p = 0.04) but diastolic BP increased (p = 0.01).
No significant differences were found in weight, duration of diabetes or lipid profiles (p >
0.05). On the other hand, there were significant difference in gender (p < 0.001); socio-
economic status (p<0.001); smoking and alcohol status (p<0.001); and BMI (p=0.018) between
the study groups (Table 1).
Primary Endpoint – Risk of All-cause Mortality and Cardiovascular (CV) Events
Crude Mortality Rates: There were 1025 deaths in the study population after a 5-year follow
up period, with a total follow-up time of 71,624 person-years. The proportion of mortality
significantly decreased across the group from 8.5% in group 1to 3.2% in group 4 (p-value for
trend = 0.012). Similarly, the 5-year probability of survival for all-cause mortality was
significantly lower in group 1 (89%) than in group 2 (90%), group 3 (95%) and group 4 (96%)
(Log rank test p-value < 0.001) (Figure 1). The overall crude mortality rate was 14.3 per
1000person-years (95% CI: 13.5 to 15.2) with the greatest mortality rate in group 1 - 21.7 per
1000 person-years (95% CI: 19.8 – 23.7) and the least in group 4 - 8.1 per 1000 person-years
(95% CI: 6.9 – 9.5) (Figure 2).
Risk of All-cause Mortality: Compared to group 1 (patients with low eGFR + high ACR), the
risk of all-cause mortality was 6% lesser (aHR: 0.94; 95%CI: 0.79 to1.12) in group 2; 20%
8lesser (aHR: 0.80; 95%CI: 0.68 to 0.96) in group 3; and 28% lesser; (aHR: 0.72; 95%CI: 0.59
to 0.87)in group 4, following adjustment for confounders (see Table 2).
Secondary Endpoints – Risk of Composite MACE and Cardiovascular Events.
Crude Event Rates: As shown in Table 2, a total of 1,794 composite events of MACE
occurred after a 5-year follow up period, amounting to 63,698 person-years. This signified a
crude event rate of 28 per 1000 person-years (95%CI: 27 – 30). Group 1 had the greatest
proportion of the events (Table 2), as well as the lowest probability of survival (80%) compared
to 83%, 90% and 91% in groups 2, 3 and 4 respectively, after 5 years (Log rank test p-value <
0.001, Figure 3A).
Similarly, a total of 764 cardiovascular events were recorded after 5 years (Crude event rate:
12 per 1000 person-years; within a total of 63,746 person-years. The crude incidence rates of
CV events significantly decreased from Group 1 to 4 (p-value for trend <0.001).Similarly, the
5-year survival curve showed the same pattern (Log rank test p-value < 0.001, Figure 3B)
Risk of Composite MACE and Cardiovascular Events: Table 2 also shows that the risk of
composite MACE was 7% lesser (aHR: 0.93; 95%CI: 0.82 to1.07) in group 2; 18% lesser
(aHR: 0.82; 95%CI: 0.72 to 0.93) in group 3; and 27% lesser; (aHR: 0.73; 95%CI: 0.63 to 0.84)
in group 4 compared to group 1 patients (with low eGFR + high ACR) following adjustment
for confounders.
Similar pattern was shown in the risk of cardiovascular events in which there were 7%, 40%
and 46% reductions in the risk of stroke and MI in groups 2, 3 and 4 respectively, compared to
group 1 (Table 2)
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In this study of 18,227 patients with insulin treated T2D, we found that the combination of
reduced eGFR with increased ACR was associated with the greatest risk of premature death,
followed closely by those with reduced eGFR and normal ACR levels. This observation
demonstrates that quantitative information about eGFR and albuminuria status is an
independent predictor of total mortality, thus expanding prior observations and supporting the
hypothesis that eGFR and ACR provides synergistic insight into the association between
diabetic kidney disease and total mortality risk, even in this cohort of insulin treated T2D,
which by definition is at high risk of CV disease and mortality. Interestingly we observed that
individuals with reduced eGFR but normal ACR has a higher risk of mortality compared with
those with normal eGFR but raised ACR.
While it had long been recognised that individuals with reduced eGFR had high rates of
cardiovascular disease, [24] it was not until 2004 when Go and colleagues demonstrated a large
exponential increase in the age-standardised rate for all-cause mortality and cardiovascular
events over a three-year period in subjects with eGFR <60 mL/min. Subsequently, CKD
Prognosis Consortium [25] provided a more comprehensive evidence about the prognostic
impact of eGFR and albuminuria on mortality and kidney outcomes. In addition to eGFR,
proteinuria, either measured as total urinary protein or as urine albumin, is also a potent
predictor of mortality and cardiovascular risk [1,2]. This was again supported by the
observation from the CKD Prognosis Consortium which demonstrated a linear increase in the
risk of all-cause and cardiovascular mortality as urine albumin-to-creatinine ratio increases
[25]. This increase in risk is independent of eGFR such that there is an additive effect of
proteinuria on the risk of death or events at any level or stage of GFR.
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While both eGFR and albuminuria independently associate with increased risk of
cardiovascular disease, a key question for the practising clinician is whether they add anything
to improve mortality prediction above the known traditional risk factors for cardiovascular
disease such as age, hypertension or hyperlipidaemia among individuals who are already at
high risk of premature death – as is the case in our insulin treated cohort here. To this end, our
analysis for eGFR and albuminuria as a predictor of total mortality, has indeed independently
adjusted for conventional cardiovascular risk factors. In contrast to our study, in the analysis
of 27,000 patients in the TRANSCEND and ONTARGET randomised clinical trial who were
at high cardiovascular risk, the addition of eGFR and albuminuria did not amount to a reduction
in the number of subjects classified into the intermediate risk group [26]. Finally the
PREVEND study group assessed the value of kidney measure to predict a composite endpoint
of all-cause and cardiovascular mortality as well as incident cardiovascular events [27]. In this
study, both eGFR and albuminuria were assessed separately against a model using Framingham
cardiovascular risk factors. Albuminuria but not eGFR was associated with improved risk
prediction. Of note, none of these studies were conducted specifically in people with T2D.
Thus, mortality prediction in people with T2D, specifically those who are on insulin, represent
a unique patient cohort, where combining eGFR and albuminuira offers additional
prognostication for mortality outcome. However, whether increased ACR or reduced eGFR is
a cause or simply a risk marker of mortality risk such that reducing ACR or increasing eGFR
would improve mortality outcomes remains unclear and is beyond the remit of this present
study. Nonetheless, in the context of albuminuria in people with T2D, recent data suggest that
in addition to Renin Angiotensin System inhibitors, several glucose lowering treatment such
as sodium-glucose cotransporter-2 inhibitors [28,29], and glucagon-like peptide-1 agonist
[30,31], have been shown to improve ACR, as well as CV mortality outcomes and induce
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weight loss. While the mechanism for the reduction of mortality outcome remains unclear,
concurrent use of these glucose lowering therapy with insulin are used widely. In a previous
study within this same population cohort, we showed that the use of GLP-1 with insulin was
associated with reduced CV event and total mortality compared with insulin alone [23]. Thus
identification of patients at high risk of CV events based on ACR and eGFR status, would not
only trigger application of aggressive CV reduction strategy, but also concurrent use of
appropriate glucose lowering therapies with favourable effects of weight, albuminuria and CV
outcomes.
While it is likely that the majority of patients within this cohort have CKD due to diabetic
nephropathy, it is conceivable that other underlying aetiologies of albuminuria associated with
CKD are also present. Specifically, Obesity-related glomerulopathy (ORG) has increasingly
been reported in more and more obese patients without overt diabetes and pre-existing renal
diseases [32]. It is a secondary form of focal and segmental glomerulosclerosis (FSGS)
manifested as proteinuria and progressive renal dysfunction [33]. This is relevant within this
cohort, due to the well recognised association between insulin treatment with adverse weight
outcomes. Furthermore, previous studies have shown that weight loss intervention benefited
remission of proteinuria in patients with ORG. [34].
The main strength of our study derives from the inclusion of a large cohort of patients with
T2D receiving insulin therapy in a real-world population which is largely representative of the
UK population. This implies that our findings will be generalizable to various population that
share similar demographics. The large cohort of patients studied here provides adequate
statistical power and also contains information on other time-varying covariates to adjust for
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possible confounders. We adjusted for a large set of factors that could have differed at the
baseline. Nevertheless, some residual confounding in our study could persists. For example,
our classification of albuminuria was largely based on a single measurement, in contrast to
current recommendation, in which at least two measurements are required. Nonetheless, a
single measure of urinary albumin within a large patient cohort provides a great deal of
predictive information. In addition, as is the case in all studies of CV or ESRD risk associated
with eGFR and albuminuria, the effect of competing hazards may bias estimates of risk. This
is because elevated ACR and low eGFR are also risk factors for non-renal diseases, associated
differential mortality in high-risk individuals may confound hazard ratio estimates for CV
events. Lastly, changes after baseline in medications and subsequent changes in glycaemic
indices or blood pressure were not evaluated in this analysis and therefore cannot account for
any differences that might influence the association between ACR and outcomes.
In conclusion, the combination of elevated levels of ACR and reduced eGFR, are independently
associated with increased risk of all-cause mortality in insulin treated patients with T2D, even
after adjusting for known CV risk factors. This risk of mortality is followed closely with the
group who had reduced eGFR but normal ACR. In view of recent advances in the management
of CV disease and proteinuria in people with T2D, beyond conventional CV risk management
strategy, this information will provide useful information to identify and prognosticate high
risk patients with T2D patients who are in insulin to receive additional cardio-protective
management strategy.
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Legend
Table 1 - Baseline Characteristics
Table 2 - Comparison of number of events, incidence rate and risk of the Primary and
Secondary endpoints between the treatment groups
Figure 1 - Kaplan-Meier survival analysis plot for the primary endpoint –all cause mortality
(log-rank test p value < 0.001)
Figure 2 – Graph of the Crude Incidence rate for primary endpoint – All-cause mortality.
(Group 1: Low eGFR + High ACR (eGFR <60 and ACR ≥300); Group 2: Low eGFR +Low 
ACR (eGFR <60 and ACR <300); Group 3: High eGFR + High ACR (eGFR ≥60 and ACR 
≥300); and Group 4: High eGFR + Low ACR (eGFR ≥60 and ACR <300) 
Figure 3 - Kaplan-Meier survival analysis plots for the secondary endpoint (A) 3-point
composite of MACE (log-rank test p value < 0.001); (B) Cardiovascular Events (log-rank test
p value < 0.001)
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Table 1: Baseline characteristics
Categories
(Number)
Low eGFR +
High ACR
(Group 1)
Low eGFR +
Low ACR
(Group 2)
Hi eGFR +
Hi ACR
(Group 3)
Hi eGFR +
Low ACR
(Group 4)
Total
(5,563) (2,522) (5,511) (4,631) (18,227)
Demographics
Age (yrs), Mean (SD) 67.1 (11.9) 66.7 (11.5) 57.7 (13.5) 56.8 (13.5) 61.5 (13.6)
Gender, No. (%)
Male 2820 (51) 1219 (48) 3079 (56) 2577 (56) 9,695 (53.2)
Townsend deprivation, No. (%)
Least deprived 1128 (21) 514 (21) 999 (19) 946 (21) 3587 (19.7)
2nd quintile 1093 (21) 481 (20) 1043 (20) 880 (20) 3497 (19.2)
3rd quintile 1142 (21) 519 (21) 1116 (21) 953 (21) 3730 (20.5)
4th quintile 1133 (21) 515 (21) 1160 (22) 955 (21) 3763 (20.7)
Most deprived 832 (16) 387 (16) 913 (17) 727 (16) 2859 (15.7)
Smoking status, No. (%)
Non-smoker 2760 (50) 1237 (49) 2613 (47) 2251 (49) 8861 (48.6)
Ex-smoker 2175 (39) 997 (40) 1944 (35) 1625 (35) 6741 (37.0)
Current smoker 628 (11) 288 (11) 954 (17) 755 (16) 2625 (14.4)
Alcohol status, No. (%)
Non-drinker 1919 (34) 875 (35) 1762 (32) 1360 (29) 5916 (32.5)
Ex-drinker 679 (12) 285 (11) 592 (11) 512 (11) 2068 (11.4)
Current drinker 2965 (53) 1362 (54) 3157 (57) 2759 (60) 10,243 (56.2)
Clinical Parameters, Mean (SD)
HbA1c (%) [mmol/mol] 8.7 (1.8) [72] 8.5 (1.7) [67] 8.8 (1.9) [73] 8.6 (1.8) [70] 8.7 (1.8) [72]
BMI (kg/m2) 32.7 (6.7) 32.6 (6.7) 32.4 (6.9) 32.3 (7.0) 32.5 (6.9)
Diabetes duration* (yrs) 4.9 (4.9) 4.9 (5.4) 3.9 (4.6) 3.7 (4.7) 4.3 (4.9)
Duration on insulin (yrs) 4.3 (6.8) 4.5 (6.5) 3.6 (5.9) 3.6 (6.1) 3.9 (6.4)
Weight (Kg) 91.0 (18.4) 89.7 (18.6) 92.2 (19.2) 91.4 (18.6) 91.3 (18.7)
Height (m) 1.7 (0.1) 1.7 (0.1) 1.7 (0.1) 1.7 (0.1) 1.7 (0.1)
SBP (mmHg) 138.8 (23.6) 135.9 (22.6) 136.5 (23.0) 133.4 (22.3) 136.3 (23.0)
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DBP (mmHg) 74.4 (10.9) 75.1 (10.9) 76.8 (10.7) 77.4 (10.6) 76.0 (10.8)
eGFR (mls/min/1.73m2) 42.9 (12.7) 46.3 (10.8) 76.8 (12.8) 79.1 (14.0) 62.9 (21.2)
TC (mmol/l) 4.5 (1.3) 4.3 (1.2) 4.7 (1.4) 4.5 (1.3) 4.5 (1.3)
HDL (mmol/l) 1.2 (0.4) 1.2 (0.4) 1.2 (0.4) 1.3 (0.5) 1.2 (0.4)
LDL (mmol/l) 2.3 (1.1) 2.2 (1.0) 2.5 (1.1) 2.4 (1.1) 2.4 (1.1)
Triglyceride (mmol/L) 2.2 (1.2) 2.0 (1.2) 2.1 (1.2) 1.8 (1.2) 2.0 (1.2)
Albumin (g/L) 4.0 (0.4) 4.0 (0.4) 4.1 (0.4) 4.1 (0.4) 4.0 (0.4)
BMI Categories, No. (%)
Normal 696 (13) 316 (13) 762 (14) 681 (15) 2455 (13.5)
Overweight 1315 (24) 594 (24) 1315 (24) 1119 (24) 4343 (23.8)
Obese 3552 (64) 1612 (64) 3434 (62) 2831 (61) 11,429 (62.7)
GLTs, No. (%)
Metformin 4668 (83.9) 2105 (83.5) 4807 (87.2) 4013 (86.7) 15,593 (85.6)
Sulphonylurea 4339 (78.0) 1951 (77.4) 4129 (74.9) 3375 (72.9) 13,794 (75.7)
Thiazolidinedione 1696 (30) 755 (30) 1803 (33) 1500 (32) 5,754 (31.6)
GLP-1RA 454 (8) 194 (8) 732 (13) 563 (12) 1,943 (10.7)
SGLT2i 15 (0) 7 (0) 35 (1) 28 (1) 85 (0.5)
Glinides 262 (5) 108 (4) 238 (4) 182 (4) 790 (4.3)
DPP4i 735 (13) 289 (11) 840 (15) 705 (15) 2,569 (14.1)
Use of Medications, No. (%)
Aspirin 5459 (98) 2468 (97) 5232 (96) 4348 (98) 17,507 (96.1)
Antihypertensive 5175 (95) 2332 (94) 4634 (89) 3795 (87) 15,936 (87.4)
- ACE inhibitors 4,616 (85) 2,073 (84) 4,043 (77) 3,291 (76) 14,023 (80)
- ARBs 1,865 (34) 814 (33) 1,501 (29) 1,185 (27) 5,365 (31)
- Calcium channel blockers 3,363 (62) 1,478 (60) 2,693 (52) 2,110 (49) 9,644 (55)
- Beta-blockers 3,085 (57) 1,352 (55) 2,421 (46) 2,020 (46) 8,878 (51)
LLTs 4955 (91) 2257 (91) 4799 (92) 3965 (91) 15,976 (87.7)
Comorbidities, No. (%) c
CHD 2003 (36) 906 (36) 1393 (25) 1158 (25) 5,460 (30.0)
PAD 924 (17) 395 (16) 626 (11) 463 (10) 2,408 (13.2)
Heart Failure 1029 (18) 444 (18) 577 (10) 407 (9) 2,457 (13.5)
Hypoglycaemia 1147 (21) 497 (20) 831 (15) 710 (15) 3,185 (17.5)
*Diabetes duration is the period between the diagnosis of diabetes to the initiation of Insulin therapy
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Abbreviations:
GLP-1RA (Glucagon-like peptide-1 receptor agonist); SGLT2i (Sodium-glucose Cotransporter-2 (SGLT2) Inhibitors); DPP4i (Dipeptidyl-peptidase 4 inhibitors); GLTs (Glucose
Lowering Therapies); BMI (body mass index); SBP (systolic blood pressure); DBP (diastolic blood pressure); HbA1c (hemoglobin A1c); HDL (high-density lipoprotein); LDL (low-
density lipoprotein); TC (total cholesterol); eGFR (estimated glomerular filtration rate); LLTs (lipid lowering therapies); PAD (peripheral arterial disease); CHD (coronary heart
disease); ACR (albumin creatinine ratio); ACEi (Angiotensin Converting Enzyme Inhibitors); ARBs (Angiotensin II Receptor Blockers); SD (standard deviation)
Table 2
Low eGFR +
High ACR
(Group 1)
Low eGFR +
Low ACR
(Group 2)
Hi eGFR +
Hi ACR
(Group 3)
Hi eGFR +
Low ACR
(Group 4)
Total
5,563 2,522 5,511 4,631 18,227
All-Cause Mortality
No of events/person-years 471/21,747 195/9999 211/21,645 148/18,233 1025/71,624
Absolute ratesa (95%CI)b 21.7 (19.8 – 23.7) 19.5 (17.0 – 22.4) 9.7 (8.5 – 11.2) 8.1 (6.9 – 9.5) 14.3 (13.5 – 15.2)
aHRc (95%CI) 1 (reference) 0.94 (0.79 – 1.12) 0.80 (0.68 – 0.96) 0.72 (0.59 – 0.87) -
p-value - 0.515 0.013 0.001 -
3-point Composite MACE
No of events/person-years 773/18,604 324/8,681 400/19,638 297/16774 1794/63,698
Absolute ratesa (95%CI)b 41.5 (38.7 – 44.6) 37.3 (33.5 – 41.6) 20.4 (18.5 – 22.5) 17.7 (15.8 – 19.8) 28.2 (26.9 – 29.5)
aHRc (95%CI) 1 (reference) 0.93 (0.82 – 1.07) 0.82 (0.72 – 0.93) 0.73 (0.63 – 0.84) -
p-value - 0.319 0.002 <0.001 -
Cardiovascular Events
No of events/person-years 299/18,625 129/8,692 189/19,648 147/16779 764/63,746
Absolute ratesa (95%CI)b 16.0 (14.3 – 18.0) 14.8 (12.5 – 17.6) 9.6 (8.3 – 11.1) 8.7 (7.5 – 10.3) 12.0 (11.2- 12.9)
aHRc (95%CI) 1 (reference) 0.93 (0.76 – 1.14) 0.60 (0.50 – 0.71) 0.54 (0.45 – 0.66) -
p-value - 0.486 <0.001 <0.001 -
a Absolute Rate at 1000 person-years
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b95% CI – 95% Confidence Interval
caHR (Adjusted Hazard Ratio). Adjusted for age, gender, duration of diabetes, Systolic BP, diastolic BP, HbA1c and Socio-economic status
